Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 4 Urinary Bladder Neoplasms 3 Acrocephalosyndactylia 3 Stomach Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

pembrolizumab 248 Nivolumab 223 Ipilimumab 203 Cyclophosphamide 120 aldesleukin 119 Interleukin-2 90 trametinib 65 Dacarbazine 64 fludarabine 62 Vemurafenib 60 Temozolomide 60 dabrafenib 59 fludarabine phosphate 55 Radiosurgery 43 sargramostim 39 Bevacizumab 39 Biopsy 38 incomplete Freund's adjuvant 35 binimetinib 35 Paclitaxel 34 Radiotherapy 32 Cisplatin 32 Magnetic Resonance Spectroscopy 30 encorafenib 29 atezolizumab 29 Carboplatin 29 cobimetinib 28 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡